stockrowGeneDx Holdings Corp.
WGS Healthcare Diagnostics & Research
GeneDx Holdings Corp.’s revenue for fiscal 2025 (year ended December 2025) was $427.5 million, up 40.0% from fiscal 2024.
- Revenue
- +11.4%
- EPS
- −257.9%
- Free cash flow
- −585.6%
- Total debt
- +87.4%
Quarter to June 2026, against a year earlier
Follow WGS
Alert me
GeneDx Holdings Corp. (WGS) Gross margin
GeneDx Holdings Corp.'s gross margin over the twelve months to 30 June 2026 was 69.4%, down 0.4 percentage points from fiscal 2025 (69.7%). Over the past ten years it has ranged from −11.4% (fiscal 2022) to 69.7% (fiscal 2025) — the current reading is the highest in ten years. That is above the Diagnostics & Research industry median of 48.3% and above the Healthcare sector median of 53.9%.
Gross margin, annual
Embed this chart
Annual newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| FY2025 | 69.7% | 6.10 |
| FY2024 | 63.6% | 19.21 |
| FY2023 | 44.4% | 55.83 |
| FY2022 | −11.4% | (3.58) |
| FY2021 | −7.82% | (10.07) |
| FY2020 | 2.25% | (39.95) |
| FY2019 | 42.2% | — |
Quarterly newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| Jun 2026 | 68.4% | 1.66 |
| Mar 2026 | 66.7% | (2.94) |
| Dec 2025 | 69.7% | (2.75) |
| Sep 2025 | 72.4% | 3.36 |
| 19 more quarters | Free account |
Against its own ten years
Gross margin against peers
| Company | Gross margin |
|---|---|
| CSTL Castle Biosciences, Inc. compare | 77.1% |
| ADPT Adaptive Biotechnologies Corporation compare | 74.2% |
| VCYT Veracyte, Inc. compare | 72.0% |
| CDNA CareDx, Inc. compare | 71.0% |
| WGS GeneDx Holdings Corp. | 69.4% |
| OPK OPKO Health, Inc. compare | 46.2% |
| NEO NeoGenomics, Inc. compare | 44.8% |
| PSNL Personalis, Inc. compare | 16.7% |
| FRNM Freenome, Inc compare | — |
| Diagnostics & Research industry median | 48.3% |
| Healthcare sector median | 53.9% |
| Market median | 45.1% |
What Gross margin is
Gross Margin tells an investor how much of each sale a company keeps after paying the direct costs of making or buying what it sells.
Gross Profit ÷ Revenue
More on WGS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement